spacer
home > ebr > spring 2007 > pushing biobank standardisation
PUBLICATIONS
European Biopharmaceutical Review

Pushing Biobank Standardisation

Establishing an effective biomedical tissue management system is an integral part of moves to standardise and harmonise biobanking practices, explains Dr Achim Quandt of QIAGEN GmbH

In cancer research, as with other areas of biomedical research, a major issue facing researchers is the great variation in the methods employed by different labs for collecting, storing and analysing biological samples. This affects the quality and comparability of research data, and can only be resolved by the widespread adoption of standardised and quality-controlled protocols. Such protocols in case-control, cohort and other epidemiological studies are required to facilitate the discovery and validation of relevant disease biomarkers and, ultimately, the development of diagnostics and therapeutics.

Initiatives at the national and international level to standardise and harmonise biobanking practices have already begun. In Europe, the European Commission and the Wellcome Trust organised a conference in 2005 to discuss the current state of biobanks in Europe and to propose future strategies, including greater harmonisation of programmes and standards and greater standardisation of protocols. Proposals will be submitted to the 7th Framework Programme for Research and Technological Development (FP7), an EU programme with a budget of over ˆ50 billion to fund trans-European research.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Achim Quandt joined QIAGEN GmbH, a leading supplier of sample and assay technologies, as Global Product Manager for gene expression analysis products in April 2000. His current role involves global responsibility for the biomedical research market segment, including biomedical tissue management and biobanking. Prior to this, he spent five years working in sales and marketing at molecular diagnostics companies. Achim has a PhD in Molecular Biology and has studied at Bielefeld University, Germany, and the University of Edinburgh, UK.
spacer
Dr Achim Quandt
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

The Importance of ADCC in Assessing Clinically Relevant Differences

Sartorius Stedim BioOutsource Ltd

Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more about these molecules.
More info >>

 
Industry Events

ELRIG Drug Discovery 2019 – Looking Back to the Future

5-6 November 2019, ACC, Liverpool

Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at ACC in Liverpool. This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 40 world-class speakers with 6 main session tracks. In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement